TIANJIN DEV (00882) announced its annual results, with a profit attributable to shareholders of 0.548 billion HKD, a year-on-year decrease of 13.78%. It plans to declare a final dividend of 8.82 HK cents per share.
TIANJIN DEV (00882) announced its annual results for the year ending December 31, 2024, with group revenue of 33.59...
Express News | Tianjin Development Holdings FY Net Income HKD 548.1 Million
Express News | Tianjin Development - Proposed Final Dividend of HK8.82 Cents per Share
TIANJIN DEV: Announcement of Final Results for the year ended 31 December 2024
Tianjin Lisheng's Profit Falls in 2024; Shares Down 3%
TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical (002393.SZ) had a net income of 0.185 billion yuan for the year 2024, a decrease of 49% year-on-year.
TIANJIN DEV (00882) announced Tianjin Lisheng Pharmaceutical (002393.SZ) as of December 31, 2024...
TIANJIN DEV: Audited Financial Results for the year ended 31 December 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.
TIANJIN DEV: Date of Board Meeting
Tianjin Lisheng Pharmaceutical Buys Back Shares Worth 129 Million Yuan
TIANJIN DEV (00882.HK): Xia Binhui has been appointed as Executive Director and Deputy General Manager.
Gelonghui reported on December 30 that TIANJIN DEV (00882.HK) announced that the Board of Directors has appointed Xia Binhui as the company's executive director and deputy general manager, effective from December 30, 2024.
TIANJIN DEV (00882): Xia Binhui has been appointed as Executive Director.
TIANJIN DEV (00882) announced that Xia Binhui has been appointed as the company's executive Director and vice general manager, starting from 2024...
Express News | Tianjin Development Holdings Ltd - Xia Binhui Appointed as Executive Director
Tianjin Development Subsidiary to Repurchase Shares, Grant Shares Under Share Award Scheme
Tianjin DEV (00882.HK) subsidiary Tianjin Lisheng Pharmaceutical plans to repurchase shares and adopt a stock incentive plan.
On December 20, Grizzly Holdings announced that TIANJIN DEV (00882.HK) has approved a share buyback plan at the Board of Directors of Tianjin Lisheng Pharmaceutical (a non-wholly-owned subsidiary indirectly listed on the Shenzhen Stock Exchange) on December 20, 2024. Accordingly, starting from December 21, 2024, within a period of twelve months, Tianjin Lisheng Pharmaceutical is allowed to repurchase its ordinary shares through centralized bidding on the Shenzhen Stock Exchange at the current market price, with a total amount not less than 76.5 million yuan and not exceeding 0.153 billion yuan. The Board of Directors of Tianjin Lisheng Pharmaceutical recommends that this be approved by its Shareholders at the Shareholders' meeting.
Express News | Tianjin Development - Unit to Conduct Repurchase of Ordinary Shares for Not Less Than RMB76.5 Mln and up to RMB153 Mln
Express News | Tianjin Development -Co to Borrow From Revolving Loan Facility of HK$100 Mln
Tianjin Development Renews Service Contracts With Associate
tianjin dev (00882): tianjin lisheng pharmaceutical's net income attributable to parent company for the first three quarters was 0.169 billion yuan
Tianjin dev (00882) announced that its indirectly non-wholly-owned subsidiary tianjin lisheng pharmaceutical has until September 3, 2024...
Express News | Tianjin Development - 9-Mth Net Profit Attributable RMB169.3 Mln for Tianjin Lisheng Pharmaceutical
TIANJIN DEV: Unaudited Financial Results for the nine months ended 30 September 2024 of Tianjin Lisheng Pharmaceutical Co., Ltd.